McKesson is trading at $923.83, up 5.63%, with no verified company-specific catalyst identified for September 18, 2026.

  • Recent coverage highlighted raised fiscal 2027 EPS guidance and oncology expansion, but those announcements preceded September 18.
  • Broader indexes were mixed, offering insufficient evidence for a market-wide explanation.
  • The move remains unexplained pending additional filings or news.